Pancreatic Cancer Research

ResearcherJesse Brown VA Medical CenterActive in the last 2 years

Thao D. Pham

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7547-0945; OpenAlex author ID A5039554820. Sources: OpenAlex.

Their work

Papers
8 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
17
Papers, trials and grants by year

2021: 2 papers · 2022: 3 papers · 2023: none · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 8

  1. Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7. First author DOI 10.1021/acschembio.6c00580↗
  2. Targeting BCL2 with Venetoclax Enhances the Efficacy of the KRASG12D Inhibitor MRTX1133 in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-3574↗
  3. Trametinib Potentiates Anti-PD-1 Efficacy in Tumors Established from Chemotherapy-Primed Pancreatic Cancer Cells. Co-author DOI 10.1158/1535-7163.mct-23-0833↗
  4. Gα13 loss in Kras/Tp53 mouse model of pancreatic tumorigenesis promotes tumors susceptible to rapamycin. Co-author DOI 10.1016/j.celrep.2022.110441↗
  5. XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer. Co-author DOI 10.1073/pnas.2116764119↗
  6. Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer. Co-author DOI 10.1073/pnas.2200143119↗
  7. Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma. First author DOI 10.1021/acsmedchemlett.1c00376↗
  8. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Co-author DOI 10.3390/cancers13030440↗

Closest collaborators

The 17 strongest of 17 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hidayatullah G. Munshi · 8 shared papers, 2021–2026 · strength 1.52
  2. Mario A. Shields · 4 shared papers, 2021–2024 · strength 0.76
  3. Jeffrey H. Becker · 3 shared papers, 2024–2026 · strength 0.76
  4. Daniel R. Principe · 4 shared papers, 2021–2024 · strength 0.63
  5. Karl A. Scheidt · 2 shared papers, 2021–2026 · strength 0.49
  6. Patrick W. Underwood · 3 shared papers, 2021–2022 · strength 0.40
  7. David J. Bentrem · 2 shared papers, 2021–2024 · strength 0.35
  8. Gina M. Connors · 1 shared paper, 2026 · strength 0.32
  9. Ajay Nmn Rana · 2 shared papers, 2022 · strength 0.27
  10. Jose Gilberto Trevino · 2 shared papers, 2021–2022 · strength 0.26
  11. Dhavan Shah · 1 shared paper, 2024 · strength 0.22
  12. Ada Jade Kwong · 1 shared paper, 2021 · strength 0.17
  13. Sandeep Kumar · 1 shared paper, 2022 · strength 0.14
  14. Jose Trevino · 1 shared paper, 2022 · strength 0.14
  15. Dinesh Thummuri · 1 shared paper, 2022 · strength 0.13
  16. Suneel Deepak Kamath · 1 shared paper, 2022 · strength 0.13
  17. Daohong Zhou · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.